Browse grants

National Institutes of Health · Amount varies

This NIH (NCI, U01) program funds research on how preanalytical variability in handling tumor tissue, blood, and other biospecimens affects clinically relevant biomarkers, to support standardization of biopsy handling and clinical assay development. Eligible applicants are research organizations including universities, colleges, government and tribal entities, and faith- or community-based organizations; it targets established research teams, not individuals or general nonprofits. Award amounts are not specified. Confirm program-specific eligibility in the full announcement.

National Institutes of Health · Amount varies

This NIH (NICHD, P41) program supports continued operation, maintenance, and dissemination of bioinformatics database resources important to research using animal models of embryonic development. Eligible applicants are U.S. research organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components of U.S. organizations are not eligible. It is intended for institutions that operate established bioinformatics resources, not individuals or general nonprofits. Award amounts are not specified.

National Institutes of Health · Amount varies

This NIH (NCATS, UM1) program funds Clinical and Translational Science Award (CTSA) hubs that join a national consortium to accelerate translational research, training, and rapid public health response. Eligible applicants are U.S. research organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible, though some foreign components are allowed. It is aimed at major academic medical and research institutions capable of operating a CTSA hub, not individuals or general nonprofits. Award amounts are not specified but such hubs are typically large, multi-year awards.

National Institutes of Health · Amount varies

This NIH/NCI U01 funds cancer etiology and early-detection biomarker research that must use the NCI-sponsored PLCO Screening Trial biospecimen resource. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets research organizations, not individuals. No award amount is specified. Projects that do not use PLCO biospecimens will not be funded, which narrows eligibility significantly.

National Institutes of Health · Amount varies

This NIH/NINDS U01 funds IND-enabling studies and planning for first-in-human testing of gene-based therapies for ultra-rare neurological and neuromuscular disorders. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible, and it targets research organizations rather than individuals. No award amount is specified. The ultra-rare gene-therapy focus makes eligibility narrow.

National Institutes of Health · Up to $500K

This NIH/NIDCD R01 funds translational research that turns basic findings into clinical tools for communication disorders such as hearing, balance, voice, speech, and language. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards reach up to about $500,000. Projects must show a clear clinical connection and practical impact, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NIMH award (R61/R33) funds feasibility work followed by clinical trials testing mental-health system interventions to improve the organization, delivery, and outcomes of mental health services. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. The focus on system-level interventions and required clinical trial make the scope narrow.

National Institutes of Health · Amount varies

This NIH/NIMH R01 funds pilot effectiveness trials of mental health treatment, prevention, and services interventions, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Studies must follow NIMH's experimental-therapeutics approach, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NIDCD R21 early-career award supports basic and clinical research by scientists beginning an independent research career in NIDCD mission areas such as hearing, balance, smell, taste, voice, speech, or language. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible. It cannot fund thesis or dissertation research, and is intended to generate preliminary data for a later R01. No award amount is specified.

National Institutes of Health · Amount varies

This NIH/NIMH award (R61/R33) funds early-stage testing of pharmacologic or device-based interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Studies must follow NIMH's experimental-therapeutics design, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NIMH R33 grant funds early-stage testing of pharmacologic or device-based interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it is aimed at research organizations rather than individuals. No award amount is specified. The study must follow NIMH's experimental-therapeutics design requirements, so the scope is narrow.

National Institutes of Health · Amount varies

This NIH/NIMH R33 grant funds pilot research developing and testing novel psychosocial therapeutic and preventive interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it is geared toward research organizations rather than individuals. The award amount is not specified in the listing. Applicants must use the experimental-therapeutics approach described, so the research focus is narrow.

National Institutes of Health · Amount varies

This NIH/NIMH award (R61/R33) funds development and testing of novel psychosocial therapeutic and preventive interventions for mental disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Work must follow NIMH's experimental-therapeutics approach, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NIMH R01 funds full-scale hybrid effectiveness-implementation clinical trials of mental health treatment, prevention, or services interventions in community and practice settings, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Trials must be well-powered and follow NIMH's experimental-therapeutics approach, so the scope is specific.

National Institutes of Health · Amount varies

This NIH/NIMH R01 funds confirmatory efficacy clinical trials of non-pharmacological and pharmacological interventions for mental disorders in adults and children, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Trials must follow NIMH's experimental-therapeutics design, so the scope is narrow.

National Institutes of Health · Amount varies

This NIH/NIMH U01 cooperative agreement funds first-in-human and early-stage clinical trials of novel investigational drugs or neuromodulatory devices for psychiatric disorders, with a clinical trial required. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; foreign organizations are not eligible, and it targets research organizations rather than individuals. No award amount is specified. It emphasizes academia-industry partnerships, so the scope is narrow.

National Institutes of Health · Amount varies

This NIH/NEI R21 funds vision-related research projects based on secondary analysis of existing datasets, including related statistical methodology development; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. The focus is limited to vision-related secondary data analysis.

National Institutes of Health · Amount varies

This NIH/NIDCD U01 cooperative agreement funds clinical trials for the treatment or prevention of communication disorders, specifically trials requiring FDA oversight, intended to establish efficacy, or carrying higher risk. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. Foreign organizations are not eligible. No award amount is specified, and the trial focus makes the scope narrow.

National Institutes of Health · Up to $750K

This NIH/NINDS award (R61/R33) funds development of in vitro and ex vivo assays and screening to identify candidate therapeutics for neurological and neuromuscular disorders; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards run up to about $750,000. The early-stage drug-discovery focus makes the scope narrow.

National Institutes of Health · Amount varies

This NIH/NINDS award (R61/R33) funds pharmacology and in vivo efficacy studies to advance candidate therapeutics for neurological and neuromuscular disorders toward further translational development. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets research organizations rather than individuals. No award amount is specified. The work is narrowly defined preclinical drug-development research.